Night Splinting for Carpal Tunnel (3.24.2023)
Mar 24, 2023
Recent News
Read ArticleDr. Jack Cush reviews the news and journal articles from the past 2 weeks on RheumNow.com. This week reviews clinical associations with SS-A, a new biomarker for SSc-ILD and cancer screening for myositis patients.
What to do about pre-clinical RA?
Much like the recent ACR Convergence, RheumNow Live’s 2023 conference led with this year’s hot topic of rheumatoid arthritis and especially what to do regarding pre-clinical RA.
https://t.co/k8LcTmlpZs https://t.co/NBBbi91Fbi
Links:
Mar 26, 2023
Our old friend, hydroxychloroquine
Dr.Arnaud ( @Lupusreference ) took the time to review one of our oldest therapies: hydroxychloroquine. He outlined how the anti-malarial medication has efficacy and widespread usage in lupus.
https://t.co/NJK7uJIqsV https://t.co/CQStRUUkUn
Links:
Mar 26, 2023
#RNL2023
Dr. Stanley Cohen: possible adverse effects of JAKi
-Herpes zoster, other infections
-Malignancy
-Occasional cytopenias
-LFTs (with DMARDs)
-Incr Cr or CPK
-Acne
-Incr lipids
-GI perf
-VTE
Which do you counsel with your patients? https://t.co/Ej0Rm2VFCk https://t.co/aiHGE1LsAr
Links:
Mar 26, 2023
#RNL2023:Kevin Deane: Anti-CCP positive leads to a 20-30% risk for articular clinical RA within 3-5 years https://t.co/UvXfC2iIEp https://t.co/zBoMiyy056
Links:
Mar 25, 2023
A Pilot Trial of Anifrolumab in Discoid Lupus
A research report in JAMA Dermatology describes the use of the type 1 interferon receptor inhibitor anifrolumab in patients with chronic discoid lupus erythematosus (DLE).
https://t.co/6jE1e9cqE5 https://t.co/CIH47LFRuQ
Links:
Mar 25, 2023
EULAR has published the 2022 update on recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). https://t.co/0fXUVv0sCR https://t.co/fT6iAOPOpc
Links:
Mar 25, 2023
Night Splinting for Carpal Tunnel
This week reviews clinical associations with SS-A, a new biomarker for SSc-ILD and cancer screening for myositis patients.
https://t.co/HtP7SV1v9f https://t.co/rzerQ3KMEF
Links:
Mar 25, 2023
LRA announces the 2023 recipients of the Lupus Innovation Award during #NationalKidneyMonth as three of this year’s seven award recipients are studying issues that come with this too-common complication.
🧵1of2 https://t.co/VZL9qJu9kF
Mar 25, 2023
Updated AAV Treatment Recommendations
AAV is a multi-organ disease, which can be complex and may vary from person to person. Types of AAV include GPA, microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA).
https://t.co/YCNGYZfSr1 https://t.co/MFs9ykm4fb
Links:
Mar 24, 2023
Our old friend, hydroxychloroquine
Dr.Arnaud ( @Lupusreference ) took the time to review one of our oldest therapies: hydroxychloroquine. He outlined how the anti-malarial medication has efficacy and widespread usage in lupus.
https://t.co/hKFLg1sogJ https://t.co/OxnbwpWygF
Links:
Mar 24, 2023
#RNL2023
Dr. Stanley Cohen: possible adverse effects of JAKi
-Herpes zoster, other infections
-Malignancy
-Occasional cytopenias
-LFTs (with DMARDs)
-Incr Cr or CPK
-Acne
-Incr lipids
-GI perf
-VTE
Which do you counsel with your patients? https://t.co/8bEEC6gt5Z https://t.co/Toy2DxnC4S
Links:
Mar 24, 2023
Treat to target approach in PsA
Systematic rev: 12-43% pts achieved target of very low disease activity or remission
Pts and docs agree: remission is primary goal, but Low disease activity is acceptable alternative
@DrLauraCoates at #RNL2023
https://t.co/XyXBAn82F1 https://t.co/W0nVdq6urq
Links:
Mar 24, 2023
Anti-mesangial autoantibodies in IgA nephropathy
EurekAlert!
Mar 23, 2023
IgA nephropathy (IgAN) is a kidney disorder characterized by the buildup of immunoglobin A (IgA) in the glomeruli, which are bundles of capillaries that filter blood in the kidney. In advanced stages of the disease, the buildup of IgA in the glomeruli disrupts kidney functioning and, in approximately 30% to 40% of cases, leads to kidney failure.
Read Article
Tofacitinib May Reduce Interstitial Lung Disease Risk in RA
MedPage Today
Mar 23, 2023
Tofacitinib (Xeljanz) in patients with rheumatoid arthritis (RA) stood out among several other biologic and targeted synthetic disease-modifying antirheumatic drugs (sDMARDs) when it came to the incidence of interstitial lung disease (ILD), a retrospective cohort study showed.
Read Article
#RNL2023: Kevin Deane: Anti-CCP positive leads to a 20-30% risk for articular clinical RA within 3-5 years
@RheumNow https://t.co/vPflDm22b2 https://t.co/7Al9I3Eidu
Links:
Mar 23, 2023
Retrospective study of Apremilast survival in 281 #psoriasis pts(22% w/ PsA) showed 1 yr drug survival=54%, less at 2 yrs (41%), 3 yrs (32%), and 4 yrs (30%). Half 1+ adverse events; D/C mostly for lack of efficacy (27%), adverse events (12%) https://t.co/2dm6H6cYNX https://t.co/F2YtzzWMdT
Links:
Mar 23, 2023
Phase 3 trial of IV 200 mg qd hydrocortisone in 800 pts admitted to ICU for severe community-acquired pneumonia. Day 28 strongly favored IV Hydrocort vs PBO for mortality (6% v 12%; P=0.006), Mech ventilation (18% vs 29.5%), vasopressors (15% v 25%) https://t.co/TqxorRAuvc https://t.co/0R7kNaKgj5
Links:
Mar 23, 2023
#RNL2023:Kevin Deane: Anti-CCP positive leads to a 20-30% risk for articular clinical RA within 3-5 years https://t.co/MZJfg2lM70 https://t.co/eOkcwd4xMz
Links:
Mar 23, 2023
The Biosimilar "Buy In"
Dr. Rachel Tate, @uptotate , shared insights into these key discussions during RheumNow Live.
https://t.co/dD3uZCNQEo https://t.co/MuN91Oqbvo
Links:
Mar 23, 2023
From the blog
The Biosimilar "Buy In"
Mar 21, 2023
The landscape of biosimilars is vast. This year alone we are expecting 17 biosimilars in rheumatology. While some pharmaceutical company and payer contracts are still under negotiation, we need to start preparing ourselves and our patients.
Drs. Jack Cush and Arthur Kavanuagh shared insights into these key discussions during RheumNow Live 2023.
Read Post
Podcasts
Night Splinting for Carpal Tunnel (3.24.2023)Mar 24, 2023-
Faith And Miracle LarryMar 17, 2023
-
RheumNow Live 2023 PreviewMar 11, 2023
Therapeutic Updates
Mechanism of Action of an Interleukin (IL)–23 Inhibitor Monoclonal Antibody in Moderate to Severe Plaque Psoriasis and Active Psoriatic Arthritis
Sponsored by Janssen Biotech, Inc.
Mar 01, 2023
This disease education update from Janssen provides an overview of an interleukin (IL)-23 inhibitor.
Read Post
